PortalPublikationenBinding of recombinant mistletoe lectin (aviscumine) to rese...

Binding of recombinant mistletoe lectin (aviscumine) to resected human adenocarcinoma of the lung

Standard

Binding of recombinant mistletoe lectin (aviscumine) to resected human adenocarcinoma of the lung. / Blonski, Katharina; Schumacher, Udo; Burkholder, Iris; Edler, Lutz; Nikbakht, Haleh; Boeters, Ina; Peters, Anja; Kugler, Christian; Horny, Hans-Peter; Langer, Martin; Wilhelm-Ogunbiyi, Karin; Witthohn, Klaus; Laack, Eckart.

in: ANTICANCER RES, Jahrgang 25, Nr. 5, 17.08.2005, S. 3303-7.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Blonski, K, Schumacher, U, Burkholder, I, Edler, L, Nikbakht, H, Boeters, I, Peters, A, Kugler, C, Horny, H-P, Langer, M, Wilhelm-Ogunbiyi, K, Witthohn, K & Laack, E 2005, 'Binding of recombinant mistletoe lectin (aviscumine) to resected human adenocarcinoma of the lung', ANTICANCER RES, Jg. 25, Nr. 5, S. 3303-7.

APA

Blonski, K., Schumacher, U., Burkholder, I., Edler, L., Nikbakht, H., Boeters, I., Peters, A., Kugler, C., Horny, H-P., Langer, M., Wilhelm-Ogunbiyi, K., Witthohn, K., & Laack, E. (2005). Binding of recombinant mistletoe lectin (aviscumine) to resected human adenocarcinoma of the lung. ANTICANCER RES, 25(5), 3303-7.

Vancouver

Blonski K, Schumacher U, Burkholder I, Edler L, Nikbakht H, Boeters I et al. Binding of recombinant mistletoe lectin (aviscumine) to resected human adenocarcinoma of the lung. ANTICANCER RES. 2005 Aug 17;25(5):3303-7.

Bibtex

@article{076f759cfc004bd6944eaf9f20bb0d34,
title = "Binding of recombinant mistletoe lectin (aviscumine) to resected human adenocarcinoma of the lung",
abstract = "BACKGROUND: Lectins, carbohydrate proteins, bind to glycoconjugates of all mammalian cells, including cancer cells. Aberrant glycosylation, detected by lectin histochemistry, can predict outcome in some tumour entities. One such lectin is aviscumine (recombinant mistletoe lectin). Aviscumine has cytotoxic effects and can therefore be used as anti-tumour therapy.MATERIALS AND METHODS: Lectin histochemistry with aviscumine was performed on primary tumour sections from resected adenocarcinoma of the lung. Staining results were then correlated with the clinical course of the patients.RESULTS: Most of the adenocarcinomas (92.5%) bound aviscumine. Kaplan-Meier analysis revealed no correlation between aviscumine binding and progression-free survival or overall survival.CONCLUSION: These results suggest that for the selected group of patients with adenocarcinoma of the lung aviscumine binding activity can not serve as a prognostic factor. More strikingly, however, aviscumine binds to malignant cells in 92.5% of the patients. This is an indicator for the use of aviscumine as a possible target for tumour therapy.",
keywords = "Adenocarcinoma, Adult, Aged, Aged, 80 and over, Disease-Free Survival, Female, Glycosylation, Histocytochemistry, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Plant Preparations, Plant Proteins, Recombinant Proteins, Ribosome Inactivating Proteins, Type 2, Toxins, Biological",
author = "Katharina Blonski and Udo Schumacher and Iris Burkholder and Lutz Edler and Haleh Nikbakht and Ina Boeters and Anja Peters and Christian Kugler and Hans-Peter Horny and Martin Langer and Karin Wilhelm-Ogunbiyi and Klaus Witthohn and Eckart Laack",
year = "2005",
month = aug,
day = "17",
language = "English",
volume = "25",
pages = "3303--7",
journal = "ANTICANCER RES",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

RIS

TY - JOUR

T1 - Binding of recombinant mistletoe lectin (aviscumine) to resected human adenocarcinoma of the lung

AU - Blonski, Katharina

AU - Schumacher, Udo

AU - Burkholder, Iris

AU - Edler, Lutz

AU - Nikbakht, Haleh

AU - Boeters, Ina

AU - Peters, Anja

AU - Kugler, Christian

AU - Horny, Hans-Peter

AU - Langer, Martin

AU - Wilhelm-Ogunbiyi, Karin

AU - Witthohn, Klaus

AU - Laack, Eckart

PY - 2005/8/17

Y1 - 2005/8/17

N2 - BACKGROUND: Lectins, carbohydrate proteins, bind to glycoconjugates of all mammalian cells, including cancer cells. Aberrant glycosylation, detected by lectin histochemistry, can predict outcome in some tumour entities. One such lectin is aviscumine (recombinant mistletoe lectin). Aviscumine has cytotoxic effects and can therefore be used as anti-tumour therapy.MATERIALS AND METHODS: Lectin histochemistry with aviscumine was performed on primary tumour sections from resected adenocarcinoma of the lung. Staining results were then correlated with the clinical course of the patients.RESULTS: Most of the adenocarcinomas (92.5%) bound aviscumine. Kaplan-Meier analysis revealed no correlation between aviscumine binding and progression-free survival or overall survival.CONCLUSION: These results suggest that for the selected group of patients with adenocarcinoma of the lung aviscumine binding activity can not serve as a prognostic factor. More strikingly, however, aviscumine binds to malignant cells in 92.5% of the patients. This is an indicator for the use of aviscumine as a possible target for tumour therapy.

AB - BACKGROUND: Lectins, carbohydrate proteins, bind to glycoconjugates of all mammalian cells, including cancer cells. Aberrant glycosylation, detected by lectin histochemistry, can predict outcome in some tumour entities. One such lectin is aviscumine (recombinant mistletoe lectin). Aviscumine has cytotoxic effects and can therefore be used as anti-tumour therapy.MATERIALS AND METHODS: Lectin histochemistry with aviscumine was performed on primary tumour sections from resected adenocarcinoma of the lung. Staining results were then correlated with the clinical course of the patients.RESULTS: Most of the adenocarcinomas (92.5%) bound aviscumine. Kaplan-Meier analysis revealed no correlation between aviscumine binding and progression-free survival or overall survival.CONCLUSION: These results suggest that for the selected group of patients with adenocarcinoma of the lung aviscumine binding activity can not serve as a prognostic factor. More strikingly, however, aviscumine binds to malignant cells in 92.5% of the patients. This is an indicator for the use of aviscumine as a possible target for tumour therapy.

KW - Adenocarcinoma

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Disease-Free Survival

KW - Female

KW - Glycosylation

KW - Histocytochemistry

KW - Humans

KW - Lung Neoplasms

KW - Male

KW - Middle Aged

KW - Neoplasm Staging

KW - Plant Preparations

KW - Plant Proteins

KW - Recombinant Proteins

KW - Ribosome Inactivating Proteins, Type 2

KW - Toxins, Biological

M3 - SCORING: Journal article

C2 - 16101142

VL - 25

SP - 3303

EP - 3307

JO - ANTICANCER RES

JF - ANTICANCER RES

SN - 0250-7005

IS - 5

ER -